Nova Mentis Life Science Corp. is pleased to announce it has received orphan drug designation from the European Medicines Agency for its propriety psilocybin drug for the treatment of fragile X syndrome, the leading genetic cause of symptoms related to autism spectrum disorder.
Category Press Release